170900.KO Dong-A St
- Market cap
- KRW 337B
- P/E
- 38.6x
- P/B
- 0.52x
- ROE
- 3.5%
- Dividend yield
- 1.87%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 170900.KO undervalued?
Graham number170900.KO trades 5.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dong-A St fundamental analysis
No fundamental analysis for Dong-A St yet.
Dong-A St stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and …
Full company profileDong-A St financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dong-A St annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 561B | 555B | 567B | 612B | 587B | 593B | 635B | 664B | 698B | 809B | 856B |
| Gross Profit | 277B | 280B | 293B | 312B | 284B | 294B | 315B | 328B | 340B | 361B | 368B |
| Operating Income | 14.8B | 23.9B | 39.4B | 56.6B | 34.0B | 15.6B | 17.2B | 11.2B | -25.0B | 623M | 28.1B |
| EBITDA | - | 21.9B | 43.0B | 117B | 58.4B | 37.7B | 46.5B | 45.1B | 29.0B | 12.6B | 58.5B |
| Net Income | 10.6B | -5.40B | 8.01B | 70.9B | 27.1B | 12.8B | 13.6B | 11.1B | -1.22B | -28.6B | 22.8B |
| EPS | - | -639 | 949 | 8,404 | 3,212 | 1,519 | 1,476 | 1,294 | -133 | -2,972 | 2,363 |
| Balance Sheet | |||||||||||
| Total Assets | 1.07T | 900B | 949B | 1.01T | 981B | 1.12T | 1.16T | 1.26T | 1.39T | 1.41T | 1.35T |
| Total Liabilities | 477B | 319B | 369B | 363B | 339B | 460B | 468B | 581B | 683B | 740B | 681B |
| Shareholders' Equity | 589B | 581B | 579B | 646B | 642B | 656B | 672B | 657B | 670B | 643B | 647B |
| Cash & Short-term Investments | 286B | 191B | 218B | 225B | 148B | 195B | 265B | 213B | 184B | 164B | 136B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.89B | 51.2B | 50.1B | 56.3B | 27.0B | 49.4B | 32.9B | 3.37B | -11.8B | 27.8B | -8.90B |
| Capital Expenditure | 22.1B | 10.7B | 7.74B | 12.7B | 37.0B | 61.1B | 68.9B | 42.0B | 32.1B | 35.6B | 28.3B |
| Free Cash Flow | - | 39.6B | 41.4B | 37.5B | -15.1B | -31.1B | -36.0B | -38.7B | -43.9B | -7.85B | -37.2B |
| Ratios | |||||||||||
| ROE | 1.8% | -0.9% | 1.4% | 11.0% | 4.2% | 2.0% | 2.0% | 1.7% | -0.2% | -4.4% | 3.5% |
| ROA | 1.0% | -0.6% | 0.8% | 7.0% | 2.8% | 1.1% | 1.2% | 0.9% | -0.1% | -2.0% | 1.7% |
| Net Profit Margin | 1.9% | -1.0% | 1.4% | 11.6% | 4.6% | 2.2% | 2.1% | 1.7% | -0.2% | -3.5% | 2.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dong-A St dividends
- Dividend yield
- 1.87%
- Forward dividend
- 700.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Mar 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 6.29B | 654 | - |
| 2024 | KRW 5.90B | 644 | - |
| 2023 | KRW 5.88B | 684 | 52.9% |
| 2022 | KRW 8.44B | 919 | 62.3% |
| 2021 | KRW 8.44B | 1,000 | 65.8% |
| 2020 | KRW 8.44B | 1,000 | 31.1% |
| 2019 | KRW 8.44B | 1,000 | 11.9% |
| 2018 | KRW 4.22B | 500 | 52.7% |
| 2017 | KRW 4.22B | 500 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Mar 10, 2026.
Who owns Dong-A St
- Insiders 46.75%
- Institutions 5.43%
- Public & others 47.82%
- Shares outstanding 9.64M
- Free float 5.15M
Dong-A St company profile
- Company name
- Dong-A St
- Ticker
- 170900.KO
- ISIN
- KR7170900005
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,649
- Fiscal year end
- December
- Address
- 64 Cheonhodaero, Seoul, South Korea
- Phone
- 82 2 920 8111
- Website
- donga-st.com
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis; Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus; DA-3880 PFS to treat renal anemia and darbepoetin-alfa; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
Dong-A St management
9- Jae-Hong ParkPresident & Director · born 1969
- GyuHong JoManaging Director
- SunJong SoManaging Director
- Yu-Seok ShinManaging Director
- SeongAe YoonHead
- Jae-Hun JungCEO, President & Director · born 1971
- DaeWoo LeeExecutive Director · born 1972
- Ms. Young-jin ChoiSenior Managing Director · born 1973
- Mr. Jin-seok JungAssistant Executive Director · born 1974